Alveolus Bio specializes in developing inhaled biotherapeutics for the prevention and treatment of chronic lung diseases. Their flagship technology, the resMIT platform, delivers targeted bacteria directly to the lungs to address fibroblast dysfunction in Idiopathic Pulmonary Fibrosis (IPF) and neutrophilic inflammation in conditions such as NCFBE and COPD.
